Abstract
Lung cancer continues to be the leading cause of cancer death worldwide. Among lung cancers, 80% are classified as nonsmall- cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). In the last years, the discovery of the pivotal role in tumorigenesis of the Epidermal Growth Factor Receptor (EGFR) has provided a new class of targeted therapeutic agents: the EGFR tyrosine kinase inhibitors (EGFR-TKIs). Since the first reports of an association between somatic mutations in EGFR exons 19 and 21 and response to EGFR-TKIs, treatment of advanced NSCLC has changed dramatically. Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to EGFR-TKIs and other targeted therapies. In advanced NSCLC patients harboring EGFR mutations, the use of EGFR TKIs in first-line treatment has provided an unusually large progression-free survival (PFS) benefit with a negligible toxicity when compared with cytotoxic chemotherapy in phase III randomized trials. Considering the findings regarding the excellent benefit and better safety profile of EGFR TKIs in EGFR mutation positive patients, these targeted therapeutic agents can be now considered as first-line treatment in this setting of patients. This review will discuss the new evidences in the role of EGFR-TKIs in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making.
Keywords: Acquired resistance, advanced NSCLC, epidermal growth factor mutation, erlotinib, first-line treatment, fluorescence in situ hybridization, gefitinib, immunohistochemistry, mutation detection, primary resistance, polymerase chain reaction, targeted therapy
Current Medicinal Chemistry
Title:The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation
Volume: 19 Issue: 20
Author(s): A. Sgambato, F. Casaluce, P. Maione, A. Rossi, E. Rossi, A. Napolitano, G. Palazzolo, M. A. Bareschino, C. Schettino, P. C. Sacco, F. Ciadiello and C. Gridelli
Affiliation:
Keywords: Acquired resistance, advanced NSCLC, epidermal growth factor mutation, erlotinib, first-line treatment, fluorescence in situ hybridization, gefitinib, immunohistochemistry, mutation detection, primary resistance, polymerase chain reaction, targeted therapy
Abstract: Lung cancer continues to be the leading cause of cancer death worldwide. Among lung cancers, 80% are classified as nonsmall- cell lung cancer (NSCLC) and are mostly diagnosed at an advanced stage (either locally advanced or metastatic disease). In the last years, the discovery of the pivotal role in tumorigenesis of the Epidermal Growth Factor Receptor (EGFR) has provided a new class of targeted therapeutic agents: the EGFR tyrosine kinase inhibitors (EGFR-TKIs). Since the first reports of an association between somatic mutations in EGFR exons 19 and 21 and response to EGFR-TKIs, treatment of advanced NSCLC has changed dramatically. Histologic profile, clinical characteristics, and mutational profile of lung carcinoma have all been reported as predictive factors of response to EGFR-TKIs and other targeted therapies. In advanced NSCLC patients harboring EGFR mutations, the use of EGFR TKIs in first-line treatment has provided an unusually large progression-free survival (PFS) benefit with a negligible toxicity when compared with cytotoxic chemotherapy in phase III randomized trials. Considering the findings regarding the excellent benefit and better safety profile of EGFR TKIs in EGFR mutation positive patients, these targeted therapeutic agents can be now considered as first-line treatment in this setting of patients. This review will discuss the new evidences in the role of EGFR-TKIs in the first-line treatment of advanced NSCLC and their implication in the current clinical decision-making.
Export Options
About this article
Cite this article as:
Sgambato A., Casaluce F., Maione P., Rossi A., Rossi E., Napolitano A., Palazzolo G., A. Bareschino M., Schettino C., C. Sacco P., Ciadiello F. and Gridelli C., The Role of EGFR Tyrosine Kinase Inhibitors in the First-Line Treatment of Advanced Non Small Cell Lung Cancer Patients Harboring EGFR Mutation, Current Medicinal Chemistry 2012; 19 (20) . https://dx.doi.org/10.2174/092986712801215973
DOI https://dx.doi.org/10.2174/092986712801215973 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
UGT1A1 Mediated Drug Interactions and its Clinical Relevance
Current Drug Metabolism Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy Melittin: A Natural Peptide with Expanded Therapeutic Applications
The Natural Products Journal Breast Cancer: Current Developments in Molecular Approaches to Diagnosis and Treatment
Recent Patents on Anti-Cancer Drug Discovery Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Natural Polyphenols and their Synthetic Analogs as Emerging Anticancer Agents
Current Drug Targets Optimizing Outcomes Following Allogeneic Hematopoietic Progenitor Cell Transplantation in AML: The Role of Hypomethylating Agents
Current Cancer Drug Targets Targeting Protein-Protein Interaction with Covalent Small-Molecule Inhibitors
Current Topics in Medicinal Chemistry MRP1-dependent Collateral Sensitivity of Multidrug-resistant Cancer Cells: Identifying Selective Modulators Inducing Cellular Glutathione Depletion
Current Medicinal Chemistry Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Vascular Endothelial Growth Factor Receptor as Target for Advanced Non-Small Cell Lung Cancer Therapy
Current Drug Targets Cancer Metastasis Treatments
Current Drug Therapy Development of A Novel System Based on Green Magnetic / Graphene Oxide / Chitosan /Allium Sativum / Quercus / Nanocomposite for Targeted Release of Doxorubicin Anti-Cancer Drug
Anti-Cancer Agents in Medicinal Chemistry EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Amyloidogenicity of p53: A Hidden Link Between Protein Misfolding and Cancer
Current Protein & Peptide Science Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT
Current Cancer Drug Targets Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology